4 Reasons to Go Long On Rigel Pharmaceuticals Inc. [RIGL]

Rigel Pharmaceuticals Inc. [RIGL] shares are up more than 40.65% this year and recently increased 0.03% or $0.08 to settle at $3.09. RIGL has a short ratio of 9.17. This implies that the market is currently less bullish on the outlook for RIGL.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 4, December 2020, Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition. According to news published on Yahoo Finance, Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020. The poster presentations will be made available on the event’s website at https://www.hematology.org/meetings/annual-meeting on Saturday, December 5 at 7:30am PT.

Analyst Birdseye View:

The most recent analyst activity for Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] stock was on November 15, 2019, when it was Resumed with an Overweight rating from Cantor Fitzgerald, which also lowered its 12-month price target on the stock from $7 to $5. On September 26, 2019, JP Morgan Resumed an Overweight rating and boosted its price target on this stock to $7. On March 01, 2019, Cantor Fitzgerald Reiterated an Overweight rating and decreased its price target from $9 to $7. On August 27, 2018, Citigroup Initiated a Buy rating and increased its price target to $8.50. On May 02, 2018, Cantor Fitzgerald Reiterated an Overweight rating and boosted its amount target on this stock to $9. On December 21, 2017, Piper Jaffray Resumed an Overweight rating and boosted its target amount on this stock to $6. On December 15, 2017, Cantor Fitzgerald Initiated an Overweight rating and improved its amount target to $6.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.23 and a peak of $5.24. Right now, according to Wall Street analyst the average 12-month amount target is $7.33. At the most recent market close, shares of Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] were valued at $3.09.


Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] most recently reported quarterly sales of 18.39 billion, which represented growth of -12.00%. This publicly-traded organization’s revenue is $363,730 per employee, while its income is -$410,393 per employee. This company’s Gross Margin is currently 99.30%, its Operating Margin is -26.00%, its Pretax Margin is -112.83, and its Net Margin is -112.83. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -46.67, -81.73, -69.09 and -69.42 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 40.29 and the whole liability to whole assets at 24.61. It shows enduring liability to the whole principal at 32.22 and enduring liability to assets at 0.20 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.96 points at 1st support level, the second support level is making up to 2.92. But as of 1st resistance point, this stock is sitting at 3.06 and at 3.12 for 2nd resistance point.

Rigel Pharmaceuticals Inc. [RIGL] reported its earnings at -$0.08 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.12/share signifying the difference of 0.04 and 33.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.1 calling estimates for -$0.13/share with the difference of 0.03 depicting the surprise of 23.10%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] is 2.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.68. Now if looking for a valuation of this stock’s amount to sales ratio it’s 6.04 and it’s amount to book ratio is 6.68.